Thank you for joining us. The webcast will start in a few minutes.

Q&A SESSION AND MATERIAL

- **Questions can be raised via the chat function**
- All report material can be downloaded on our website www.immunovia.com
- A recording will be available on immunovia.com/home/investors/

FORWARD-LOOKING STATEMENTS

IMPORTANT: The following applies to this document, the oral presentation of the information in this document by Immunovia AB (publ) (the "Company") or any person on behalf of the Company, and any question-and-answer session that follows the oral presentation (collectively, the "Information").

The Information has been prepared and issued by the Company solely for use at the presentation held by the Company in relation to the Company's operations and position. The Information has not been independently verified and will not be updated. Unless otherwise stated, and any market data used in the Information is not attributed to a specific source, are estimates of the Company, and have not been independently verified. The Information, including but not limited to forward-looking statements, applies only as of the date of this document and is not intended to give any assurances as to future results.

THE INFORMATION IS BEING MADE AVAILABLE TO EACH RECIPIENT SOLELY FOR ITS INFORMATION AND BACKGROUND.

The Information does not constitute or form part of and should not be construed as an offer or the solicitation of an offer to subscribe for or purchase any securities issued by the Company.

The Information contains forward-looking statements. All statements other than statements of historical fact included in the Information are forward-looking statements. Forward-looking statements give the Company's current expectations and projections relating to its financial condition, results of operations, plans, objectives, future performance and business. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that could cause the Company's actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which it will operate in the future. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Immunovia Q3 2026 interim report



Agenda

- PancreaSure trial and adoption
- Reimbursement and clinical studies
- Business development
- Q3 financial results
- Rights issue
- Q&A


We are pursuing clear focus areas to grow the business and create shareholder value



PANCREASURE TRIAL & ADOPTION


Q3 2026

Q3 marked our transition from the targeted advocacy stage to the volume building phase of the PancreaSure launch



1. Timing of signing a strategic partner is very difficult to forecast

36 U.S. high-risk surveillance programs have used the PancreaSure test since launch



Beth Israel Deaconess Medical Center

UCLA Health

HONORHEALTH

Stanford MEDICINE


Memorial Sloan Kettering Cancer Center

uchealth

Northwestern Medicine

MICHIGAN MEDICINE UNIVERSITY OF MICHIGAN

12 of 36 high-risk clinics have reached the adoption stage as of Sep 30



KEYS TO MOVING HIGH-RISK CLINICS FROM TRIAL TO ADOPTION

- Partnering with customers to modify surveillance protocols
- Increasing communication to encourage weekly testing, and
- Expanding relationships with the nurses, genetic counselors, and support staff who drive execution

12

CLINICS ARE NOW AT FULL ADOPTION

In Q3 we began targeting large gastroenterology practice groups

Saratoga Schenectady Gastroenterology Associates


- Saratoga Schenectady Gastroenterology Associates is our first gastroenterology group pilot
- SSGA serves patients in rural New York state, far from high-risk surveillance programs in the city
- After a successful trial with a lead gastroenterologist, we are now rolling out PancreaSure to the other 25 clinicians at SSGA
- SSGA will participate in the ASSURE registry, generating valuable real-world data on the use of PancreaSure in a GI clinic

REIMBURSEMENT & CLINICAL STUDIES

We continue to pursue multiple pathways to secure payment for PancreaSure tests

	1 Payments from Patients	2 Insurance Payments Prior to Coverage	3 Insurance Payments After Coverage
Timing	Began Sep 2025	Began Feb 2026	2027 and beyond
Expected average payment per test	$204 (2,005 SEK)	To be determined	Medicare: $897 (8,350 SEK) Private: To be determined
Update	• Collection rate is high at 80% • Self-pay payments will decline as more claims are sent through insurance • Many patients will have some cost-share	• Early results are promising • Timelines to process claims are long, so data is limited • So far, more claims are being paid and they are being paid at a higher rate than expected	• Medicare application submitted in Q3

We achieved a major milestone with the submission of our Medicare coverage submission



immunovia

September 28th, 2026

Dr. Angella Charnot-Katsikas
MolDX Program
Palmetto GBA

Re: New Local Coverage Determination Request — Blood-Based Proteomic Tests That Aid in Detection of Pancreatic Ductal Adenocarcinoma (PDAC) in High-Risk Populations

Dear Dr. Charnot-Katsikas,

On behalf of Immunovia, Inc., we respectfully submit this formal request for a new Local Coverage Determination (LCD) for blood-based proteomic tests that aid in detection of PDAC in high-risk populations. The test that is the subject of this request is **PancreaSure™**, a proprietary serum multianalyte laboratory-developed test performed exclusively in Immunovia's CLIA-certified and CAP-accredited laboratory in Durham, North Carolina.

To facilitate MolDX's review, this submission includes:

- A comprehensive dossier describing PancreaSure and the supporting analytical validity, clinical validity, and clinical utility evidence;
- Proposed LCD coverage language; and
- Complete copies of the peer-reviewed publications cited in support of this request

We would be pleased to respond to questions or provide additional information that may assist with the LCD development process.

Thank you for your consideration.

Sincerely,

Natalie Carfora
Vice President, Market Access & Reimbursement
Immunovia, Inc.
natalie.carfora@immunovia.com | 919.246.5001

- Medicare is the U.S. government health insurance for those over age 65+
- We submitted our application for coverage to MolDX on September 28
- The timeline of the review process is at the discretion of the MolDX team that reviews all submissions
- Our submission highlighted the significant burden of pancreatic cancer for those age 65 and older to encourage a priority review

PALMETTO GBA®
MolDX®

Near-term surveys and retrospective studies that support our reimbursement efforts are progressing well

Study	Methodology and Objective	Collaborators	Status
DECIDE	Physician survey of how PancreaSure changes clinical management of patients	PRECEDE The Pancreatic Cancer Early Detection Consortium	Data collection complete, analysis underway. Expect to announce results in Q4
ADHERE	Patient survey to measure interest in a blood test and how high-risk individuals would use a blood test	FORCE Facing Hereditary Cancer EMPOWERED	Results announced and being presented at conferences in Q3 and Q3
ASSURE	Observational registry study to assess the impact of real-world use of PancreaSure	Northwestern Medicine + multiple study sites	Initial sites activated; more coming in Q4
Kaiser pre-diagnostic	Case-control study to see whether PancreaSure can detect pancreatic cancer before it is found on imaging	KAISER PERMANENTE®	Expect to analyze samples in Q4

BUSINESS DEVELOPMENT OPPORTUNITIES


Response to our business development outreach is very encouraging

TARGET	STATUS
U.S. Commercialization Partners	• Targets impressed by our commercial traction and our consistent of achievement of key milestones • Will share our commercial reimbursement results in Q4
Asia Commercialization Partners	• Exploring a promising licensing opportunity with a Japanese life sciences company • Discussions ongoing with multiple prospective partners in China who are conducting due diligence
Pharmaceutical Partners	• Speaking with pharmaceutical companies with development or commercial-stage therapies for pancreatic cancer • Exploring both research and commercial collaborations with drug makers

Q3 2026 FINANCIAL RESULTS & RIGHTS ISSUE


Q3 Financial Results

- Net sales increased to 843 KSEK (101) in the third quarter – and increased to 1 598 KSEK (330) in the first 9 months 2026.
- Operating loss was 17,7 MSEK (25,1) in the third quarter – and the operating loss was 58,9 MSEK (64,0) in the first 9 months 2026.
- Losses for the third quarter amounted to 17,6 MSEK (-29,7) which represent earning per share before dilution of -0,03 SEK (-0,10). Loss for the first 9 months was 58,9 MSEK (-128,6).
- Cash burn in the third quarter was 5,0 MSEK/month, well below guidance of 8-10 MSEK/month due to lower spending on clinical studies and cost controlling.
- Cash at quarter-end of 19,6 MSEK
    - Current cash position will fund our operations until the proceeds from the rights issue are received in the end of this year.



Rights issue

- We are conducting a rights issue of units that may provide the Company with approximately SEK 63,4 million before deduction of issue costs and fees to guarantors.
    - 80% of the rights issue is secured through subscription commitments from management and the Board of Directors, who have committed to subscribe for units exceeding their respective pro rata entitlements, as well as underwriting commitments. This corresponds to approximately SEK 50 million in secured proceeds from the rights issue before issue costs and fees to guarantors
    - The secrued net proceeds from the right issue will fund operations into second quarter 2027. Potential additional proceeds from the Warrants TO4 can provide additional proceeds of SEK 31,7 million before issue costs in May 2027 and extend the runway.
- Each unit consists of two (2) shares and one (1) warrant of series TO 4.
    - Warrent TO4 subscription period from 19 April to 3 May 3 2027



We are raising capital through a rights issue to support our growth and achieve key milestones

COMMERCIAL

Targeted investment in sales and marketing to prove market demand

CLINICAL

Clinical studies to show the patient benefits of using PancreaSure to support reimbursement

OPERATIONS

General company expenses such as the cost to operate our U.S. lab

Rights issue proceeds will fund robust clinical studies to generate data supporting payer coverage decisions and reimbursement

STUDY	OBJECTIVES	METHODOLOGY	COLLABORATORS
NIH Cyst Study	Assess PancreaSure sensitivity and specificity in detecting cancer in cyst patients	Prospective controlled trial	UC San Diego Health
NIH Cyst Study	Assess whether PancreaSure can improve decisions about which cyst patients need surgery	Prospective controlled trial	UC San Diego Health
BEACON	Determine the true false-positive rate of PancreaSure. Generate data on how to proceed after a positive PancreaSure test	Prospective controlled trial	KAISER PERMANENTE®
RADAR	Measure test sensitivity in detecting pancreatic cancer in patients with suspicious imaging findings	Prospective controlled trial	KAISER PERMANENTE®

To learn more about the rights issue, please visit

investors.immunovia.com